Overexpression of Bcl-X L , an anti-apoptotic Bcl-2 family member, occurs in a majority of head and neck squamous cell carcinomas (HNSCCs) and correlates with chemotherapy resistance in this disease. Overexpression of Bcl-2 is also observed in HNSCC, albeit less frequently. We have previously shown that peptides derived from the BH3 domains of pro-apoptotic proteins can be used to target Bcl-X L and Bcl-2 in HNSCC cells, promoting apoptosis. In this report we 
INTRODUCTION
occurring compound (-)-gossypol, an inhibitor of Bcl-X L and Bcl-2, also has been shown to promote apoptosis of HNSCC cells, both in vitro and in vivo (Bauer et al., 2005; Wolter et al., 2006) . These studies have hinted at the potential therapeutic benefit of targeting Bcl-X L /Bcl-2 in head and neck cancers.
Recently, a number of small molecule inhibitors of anti-apoptotic Bcl-2 family members have been identified. Among these, the compound with the highest affinity for Bcl-X L and Bcl-2 is ABT-737 (Oltersdorf et al., 2005; Zhai et al., 2006) . ABT-737 binds anti-apoptotic Bcl-X L , Bcl-2, and Bcl-w, but shows little affinity for anti-apoptotic Mcl-1L and A1/Bfl (Oltersdorf et al., 2005) . When used as a single agent, ABT-737 induces apoptosis in the low micromolar range in small-cell lung cancer (SCLC) cells (Oltersdorf et al., 2005) , as well as cell lines and primary cells representing a variety of hematologic malignancies, including acute myeloid leukemia, follicular lymphoma, chronic lymphocytic leukemia, and multiple myeloma (Chauhan et al., 2007; Del Gaizo Moore et al., 2007; Konopleva et al., 2006; Kuroda et al., 2006; Oltersdorf et al., 2005; van Delft et al., 2006) . Monotherapeutic ABT-737 also exhibits in vivo efficacy against SCLC and leukemia xenografts (Konopleva et al., 2006; Oltersdorf et al., 2005) .
However, cell lines derived from other types of solid tumors have failed to demonstrate sensitivity to single agent ABT-737, and resistance to this compound is associated with aberrant overexpression of Mcl-1L (Chen et al., 2007; Huang and Sinicrope, 2008; Konopleva et al., 2006; Lin et al., 2006; Tahir et al., 2007; van Delft et al., 2006; Wesarg et al., 2007) . Despite these limitations, ABT-737 has shown the ability to sensitize cells derived from both solid tumor and hematopoietic malignancies to conventional anti-cancer agents (Oltersdorf et al., 2005; Tahir et al., 2007) . ABT-737 sensitizes ovarian cancer cells to carboplatin (Witham et al., 2007) (TRAIL) in pancreatic, prostate, renal, and lung cancer cells (Huang and Sinicrope, 2008; Song et al., 2008) . Additionally, ABT-737 sensitizes cells representing hematopoietic malignancies to agents including bortezomib (Paoluzzi et al., 2008) , N-(4-hydroxyphenyl) retinamide (Kang et al., 2008) , imatinib (Kuroda et al., 2006) , vincristine (Kang et al., 2007) , dexamethasone (Kang et al., 2007; Trudel et al., 2007) , and melphalan (Trudel et al., 2007) .
The sensitivity of HNSCC cells to ABT-737 has not been investigated. We report that ABT-737 is ineffective as a monotherapy against HNSCC cells, but potently synergizes with chemotherapy to kill these cells. Upregulation of Noxa was found to play an important role in mediating the synergistic effects of ABT-737 and chemotherapy drugs. Moreover, due to potent downregulation of Mcl-1L by chemotherapy drugs, the impact of ABT-737 was not limited in cells treated with synergistic combinations of ABT-737 plus chemotherapy. These findings suggest that combination of highly selective Bcl-X L /Bcl-2 targeting agents with conventional chemotherapy drugs may be an effective means for achieving synergistic anti-tumor effects in HNSCC patients.
Materials and Methods
Cell Lines and Reagents. UM-22A, UM-22B, and 1483 are human HNSCC cell lines (Lin et al., 2007) 
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This article has not been copyedited and formatted. The final version may differ from this version. and combined with floating cells. Cells were then washed twice with cold PBS and resuspended in 1X Annexin V binding buffer at a concentration of 1 X 10 6 cells/ml. Single cell suspensions (100 µl) were then transferred to 5 ml culture tubes and stained with 5 µl of Annexin V-FITC and 5 µl of propidium iodide for 15 minutes at room temperature in the dark. After staining, 1X
Annexin V binding buffer (300 µl) was added to each tube and the samples placed on ice. Twocolor flow cytometric analyses were performed using an Epics Coulter XL flow cytometer (Beckman Coulter; Fullerton, CA).
Clonogenic Assays. Cells were seeded in 100 mm dishes (3 X 10 6 /dish), grown overnight, then treated for 1 hour with ABT-737 or cisplatin, alone or in combination. Following treatment, cells were washed twice with PBS and detached from plates using trypsin. Single cell suspensions were diluted in DMEM containing 10% FBS and an equal number of cells replated into 6-well plates. The cells were grown for 12-15 days, then colonies were stained for 30 minutes in a solution of 6% glutaraldehyde, 0.5% crystal violet in water. The plates were washed in water (5-10 times) until no more dye was detected in the rinse. After air drying, colonies comprised of 50 or more cells were counted.
Immunoblotting. For immunoblotting experiments, treated cells were scraped from plates, centrifuged at 1,300 rpm for 5 minutes at 4°C, washed once in cold PBS, then lysed for 10 minutes on ice in 150 mM NaCl, 50 mM Tris pH 8.0, 0.1% SDS, 1% NP-40, 20 µg/ml aprotinin, 3 µg/ml leupeptin, 1.5 mM PMSF. The lysates were centrifuged at 14,000 rpm and (IC 50 's from 27.6-34.5 µM). Curiously, the metastatic variant UM-22B was somewhat more resistant to cisplatin than were UM-22A cells. Expression profiling of Bcl-2 family members (Supplemental Fig. 1 ) revealed that UM-22B cells exhibit elevated levels of anti-apoptotic Bcl-2 and reduced levels of pro-apoptotic Bim, which may play a role in the increased drug resistance of these cells.
As a single agent, ABT-737 was unable to overcome the inherent drug resistance of HNSCC cells. However, it should be noted that the modest activity of single agent exceeded that obtained with A-793844, which exhibited IC 50 values from 42.6 µM to greater than 100 µM. Since ABT-737 and A-793844 differ markedly in their abilities to bind Bcl-X L and
Bcl-2, this suggests that the binding of these proteins by ABT-737 alone provides a weak apoptotic stimulus for HNSCC cells. 
ABT-737 Synergizes with Chemotherapy to

ABT-737 and Chemotherapy Induce Synergistic Activation of Apoptosis Signaling.
To determine whether combinations of ABT-737 and chemotherapy drugs induce synergistic activation of apoptosis signaling in HNSCC cells, we examined processing/activation of caspase-3 and cleavage of PARP, a caspase-3/-7 substrate (Fig. 3 ). For these experiments, UM-22A cells were treated for a shorter length of time (24 hours) with 10 µM of each agent alone, or the combination of ABT-737 plus chemotherapy drug (each at 10 µM). Relatively little, if any, processing of procaspase-3 to active caspase-3 was detected in untreated cells, or in cells treated with DMSO, ABT-737 alone, cisplatin alone, or etoposide alone (Fig. 3A) . Similarly, only low and solid tumor cell lines has been shown to correlate with resistance to ABT-737 (Chen et al., 2007; Huang and Sinicrope, 2008; Konopleva et al., 2006; Lin et al., 2006; Tahir et al., 2007; van Delft et al., 2006; Wesarg et al., 2007) . Thus, the ability of cisplatin or etoposide to promote downregulation of Mcl-1L in HNSCC cells may serve to sensitize these cells to ABT-737.
We also observed that the combination of ABT-737 plus cisplatin, or ABT-737 plus etoposide, resulted in striking upregulation of Noxa, relative to untreated cells or cells treated with single agents (Fig. 4A ). Timecourse analysis revealed that Noxa was induced as early as 12
This article has not been copyedited and formatted. The final version may differ from this version. hours after co-treatment with ABT-737 and cisplatin (Fig. 4B ). Noxa is a BH3 domain-only, proapoptotic, Bcl-2 family member and is known to potently bind and inhibit Mcl-1L . To determine the role of Noxa upregulation in cell death mediated by this combination, we utilized siRNA treatment to prevent the upregulation of Noxa. As shown in Figure 737 and conventional chemotherapy drugs in promoting cell death. This contention is supported by our findings that further downregulation of endogenous Mcl-1L levels using siRNA failed to enhance killing by the ABT-737/cisplatin combination (Fig. 6A) , while enforced overexpression of Mcl-1L inhibited cell death by this combination (Fig. 6B) . These findings suggest that overexpression of endogenous Mcl-1L in HNSCC tumors will not prove an insurmountable impediment to therapies combining chemotherapy drugs and ABT-737, or next generation derivatives including ABT-263 (Tse et al., 2008) .
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This article has not been copyedited and formatted. The final version may differ from this version. using one-way ANOVA followed by Tukey's multiple comparison test. *, P < 0.01; **, P < 0.001. UM-22A cells were seeded in 100 mm dishes, grown overnight, then transfected for 24 hours with nonspecific siRNA or Noxa siRNA, as described in Materials and Methods. The transfected cells were then either left untreated, or were treated for an additional 24 hours with 0.1% DMSO, 10 µM ABT-737 alone, 10 µM cisplatin alone, or ABT-737 plus cisplatin (10 µM each).
Following treatment, cells were harvested and analyzed by immunoblotting to determine Noxa protein levels. In addition, trypan blue exclusion assays were used to determine percent cell survival. The plotted data represent the average of means from three independent experiments, and error bars represent the standard error of the means. P values were determined using oneway ANOVA followed by Tukey's multiple comparison test. *, P < 0.01 when comparing ABT-737/cisplatin-treated cells transfected with Noxa siRNA versus nonspecific siRNA. This article has not been copyedited and formatted. The final version may differ from this version. 
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